Probiotics and Herbals as a Boom in Treatment of Ulcerative Colitis

Amandeep Singh¹,², Gurmeet Singh¹, Sankha Bhattacharya¹, Neeraj Mishra³, Amisha Thakur⁴, Uttam Kumar Mandal², Raj Kumar Narang¹

¹Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India, ²Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India, ³Department of Pharmaceutics, Amity Institute of Pharmacy, Gwalior, Madhya Pradesh, India, ⁴Department of Quality Assurance, ISF College of Pharmacy, Moga, Punjab, India

Abstract

Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form, the entire colon is involved. UC is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressants are used for therapy of UC. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2, and 24.3/100,000 people years. The main challenges in the management of the disease are drug-related side effects and local targeting. To overcome these challenges, probiotics overcome drug-related adverse side effects and local targeting. On ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also nowadays explored for their use in UC.

Key words: 5-amino salicylic acid, Crohn’s disease, cytokines, Mycobacterium avium, probiotics, ulcerative colitis

INTRODUCTION

Ulcerative colitis (UC) and Crohn’s disease are chronic inflammatory disease leads to alteration of the bowel wall.¹ UC is characterized by abdominal pain, inflammation at colon region, bloody stool, discomfort feel and apart from this, various extra intestinal manifestations are available (Pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, immune mediated disease rheumatoid arthritis, asthma, and psoriasis) which are related with inflammatory bowel diseases (IBD).² assuredly there is a high degree risk of neoplasia associated with colitis. Especially in patient suffered from colonic Crohn’s disease and ulcerative panocolitis, as the UC formed in large intestine and last part of rectum, but in Crohn’s disease it is distinguished by inflammation at any region of gastrointestinal tract (GIT) as per the reviewers suggestion UC and Crohn’s disease have almost same pathophysiology and genetic pathway by which they are causing illness.³ When we talk about GIT problem, irritable bowel syndrome is also a frequent issue. It is described by abdominal pain or discomfort during the passage of gas and defecation, associated with a change in consistency and frequency of stool.⁴

INTESTINAL MICROBIOTA: AN IMPORTANT CORE

Gut flora another name of intestinal microbiota is the name given today to the microbe population living in our intestine. Gut flora consists of ten to trillions of microorganisms having more than 500 types of bacterial species.⁵ Interaction between the host and gut microbiota results in the variation of intestinal and systemic immunity against pathogens, secretion, sensation, intestinal motility, xenobiotics, growth, and development.⁶ Apart from this, microbiota have effect on the host, which are further responsible for immunological, gene expression, psychological, and psychological...
functions.[7] Some evidence has been reviewed, to find the role of microbiota in normal gut function. Clostridium difficile can cause permitting colonization with antibiotics, which disrupt the intestinal microflora, ultimately lead to diarrhea or even colitis.[8] The disruption of intestinal microbiota results in infection in the colonic region. As per the data, gut microbiota play a key role to maintain the normal GIT function, disturbance with microbiota leads to the number of diseases.[6]

**PATHOPHYSIOLOGY OF UC**

The exact pathophysiology of UC is still unknown. As per the recent findings, [Figure 1] pathogenesis of UC remains unknown, in current years a number of findings conclusion point to an over incentive or insufficient regulation of the mucosal immune system as a crucial pathophysiological pathway, and then particular emphasis can be given to the analyses of immunologic reactions or mucosal inflammation. Many factors could affect the ulcerative colitis which could ultimately bring some immunological disorders. Apart from that, the affected person could be susceptible for infection cause by Commensal intestinal microorganisms. The first main cause is the deregulation of the immune system, which controlled immune responses to the usual microflora. In maximum (i.e., 95%) cases, deregulations of the immune system expend direct from the rectum in a continuous pattern involving part or every part of the colon.[9] A second cause is the epithelial cell abnormalities and alters in the content of gut microflora that facilitates an unusual mucosal immune response. A third cause is reduced gene expression, i.e., alteration of the gene that is CARD15/NOD2. UC is a chronic condition that contains large intestine and colon, where the entire organ or a portion of gastrointestinal is affected by inflammation. UC is the IBD which continual inflammation and ulceration which expend from rectum toward the caecum and is normally related with extra interleukin (IL-13) producing where, Crohn’s disease is related to abundant production of IL-12/IL-23 and interferon-γ (IFN-γ)/IL-17, it usually involves part of ileum and colon where discontinuous ulceration and inflammation including granulomas occurs.[10]

**SIGN AND SYMPTOMS**

The main symptoms of UC are: diarrhea, abdominal pain, rectal pain, bloody stool, fever, weight loss, and malnutrition. In proctitis colitis, swelling of rectum lining and continuous sensation at the rectum site is majorly seen. In extensive colitis cramps, massive bleeding, and dilation of the colon are major symptoms and depend on the area and severity of disease.[11]

**CONVENTIONAL TREATMENT STRATEGIES OF UC**

Depending on the severity of disease accordingly, drugs are chosen, preferably anti-inflammatory drugs from 5-amino

---

**Table 1: Basic symptoms of ulcerative colitis**

| S. no. | Initial symptoms of ulcerative colitis |
|-------|---------------------------------------|
| 1.    | Nausea and vomiting lead to diarrhea  |
| 2.    | Blood in stool                        |
| 3.    | Pain                                  |
| 4.    | Arthralgia                            |
| 5.    | Fever                                 |
| 6.    | Weight loss due to loss of appetite   |

---

**Figure 1:** The basic steps which are responsible for the formation of ulcerative colitis
salicylic acid (5-ASA) class are used, i.e., mesalamine, sulfasalazine, balsalazide, and from the corticosteroid class commonly prednisone, methylprednisolone, and budesonide are given orally and rectally.[12] Prednisone and methylprednisolone suppress the immune system nonspecifically, which is used to treat moderate to severe UC. Antibiotics are used at the initial stage of UC, but not in severe conditions. Mostly ciprofloxacin, metronidazole, and vancomycin are used.[13] The next class of drug is immunomodulators, when 5-ASA and corticosteroid class of drugs are unable to show effect against UC, at that stage immunomodulators play a key role by modifying the immune response, it may take several months to work, and drugs for this class are: methotrexate and azathioprine. In another category of drug, including inhibitors of tumor necrosis factor-α (TNF-α), i.e., infliximab and adalimumab,[14] it inhibits the production of TNF-α. One more class of drugs is added recently, new immunomodulators which includes thalidomide, tacrolimus, and mycophenolate mofetil. Some herbal drugs which are effective against UC are butyrate, liquorice, slippery elm, tormentil, Boswellia serrata, and bovine colostrum.[15]

**5-ASA**

This class of drugs has anti-inflammatory action. After oral ingestion of sulfasalazine, it is initially absorbed in the jejunum, inhibits the prostaglandins which are responsible for inflammation, it is systemically absorbed after cleavage from the 5-ASA. This class of drugs has anti-inflammatory action; by inhibition of IL-1, IL-2, and nuclear factor-kappa beta (NF-Kβ), it retard the function of monocytes. As per the recent findings, sulfasalazine inhibits the sulfide production. *In vitro* study shows patients who are taking 5-ASA, the fecal content has more sulfide than the normal fecal. Side effects include headache, vomiting, rashes, and male fertility. Sulfasalazine interacts with the absorption of folic acid, hence supplement enriched with folic acid should be used during the use of sulfasalazine.[16,17]

**Corticosteroid**

Basically, they are made up of steroid moiety, generally suppress the immune system by various pathways, by inhibition of IL-1, IL-2, IL-3, IL-4, IL-5, IL-IL-8, IFN-α, and arachidonic acid. In distal proctocolitis, topical steroid is administered with the help of suppositories or enema. Side effects include mood swings, weight gain, fluid retention, cataract, myopathy, osteoporosis, and weak immune system.[18,19]

**Antibiotics**

These are effective only at the occurrence of UC but not in the chronic stage. Drugs included in this class are: Metronidazole, ciprofloxacin, vancomycin, and tobramycin. Virulent Escherichia coli strains, Mycobacterium avium, and Bacteroides spp. are linked with the pathogenesis of UC. Antibiotics decrease the concentration of bacteria by changing the composition of gut microbiota.[20,21]

**Immunomodulator**

It is a new class of drugs which is used in the treatment of UC. It includes 6-mercaptopurine and azathioprine. It inhibits the proliferation of ribonucleotide and lymphocytes by suppression of T-cell and natural killer. These drugs also show anti-inflammatory action where the side effects of this class of drugs include diarrhea, nausea, fever, arthralgias, and pancreatitis.[22]

**Inhibitors of TNF-α**

As the name indicates this class of drug act by inhibiting the TNF-α, this is responsible for the regulation of immune cells and can cause inflammation, replication, it also responds to IL-1. Drugs included in this class are adalimumab, infliximab, and golimumab. If we talk about adalimumab anti-TNF-α antibody, in recent time approved by US Food and Drug Administration for effective in moderate-to-severe UC and the side effects include chest pain, diarrhea, hives, vision problem, numbness, and itching.[23]

**Herbal drugs**

Herbal is beneficial having less side effects such as bovine colostrums, Butyrate Tormentil, Slippery elm, and Liquorice. In the case of Butyrate, it plays a major role in the regulation of gut homeostasis, control of inflammation, mucosal lesion, and cellular proliferation.[19] Bovine colostrums are rich in proline-rich polypeptides (PRPs) that have shown results in a patient with inflammation linked with an autoimmune disorder. PRPs diminish the activity of tumor factor and cause rejection of tumor. Colostrums consist of many immunoglobulins, IFN, and cytokines, which will enhance the immunity, and prevent illness.[24] Certain herbal drugs are very common to treat UC, i.e., Aloe vera, Boswellia serrata, Clicorice, Slippery elm (Ulms fulva), wheat grass (Triticum aestivum), curcumin, germinated barley foodstuff, and bromelain.

**Self-care treatment**

The prevention is always better than cure, so we have to set daily diet routines enriched with sufficient protein, carbohydrate, and little amount of fat for the smooth functioning of body. In the case of UC doctors advise to modify their diet to help and manage symptoms of the disease. Probiotics also play a beneficial role in UC, discussed later. Depending on nutritional status, multivitamins may be recommended by
Singh, et al.: Implication of probiotics and herbals in ulcerative colitis

The combination of Lactobacillus and Bifidobacterium gives a positive result in IBS. On the basis of recent finding, rare studies are available in the treatment of IBS with probiotics; most of the probiotic research is associated with IBD. These studies explore the beneficial effects of probiotic in IBS also. In some studies, probiotics are combined with probiotics to enhance the potency of formulation. The combination of prebiotic and probiotic is known as synbiotics.

| Definition                     | Description                                      |
|-------------------------------|--------------------------------------------------|
| Prebiotics                    | These are non-digestible food ingredients         |
| Probiotics                    | These are living/killed microorganism             |
| Synbiotics                    | These are combination of prebiotic and probiotic |

Probiotics boost up the stability of tight junction where probiotics have a different positive effect on epithelial barrier; with the help of tall receptors signal by increasing the production of IgA-cells the permeability of intestinal pathogen is decreased. Probiotics are also helpful in intestinal dysmotility.

Basic property of probiotics during selection for treatment of UC

It should not be toxic. It should have the efficiency to survive in intestine, must have minimum colony-forming unit count, which makes it potent. It should remain effective during the time of storage. All probiotics are not equally active; on the basis of their studies, they can be used in combination form to obtain more results.

Mechanism of probiotics in UC

Prevention of pathogen binding: probiotics inhibit the adherence of pathogen to intestine cell line; hypothetically, it produces a lining on the intestinal mucosa. Probiotics crimp the growth of pathogen bacteria and maintain intraluminal fermentation with the secretion of defensins and signal transducer (NF-KB). The role of probiotics in UC is explained in Figure 2.

Enhancement in barrier function

Probiotics are studied to enhance their effective barrier function; probiotics VSL#3 can protect the intestinal mucosa by enhancing barrier function. Tight junction protein was screwed by activation of F-38 and regulated protein kinase signaling. Probiotics exhibit an anti-inflammatory effect; previous findings show the deduction in the pro-inflammatory process by enhancement in FOXP3 mRNA expression.

Curable effect of probiotics in UC

In 2003, the first trial of VSL#3 was done on 25 patients with UC taken randomly to provide VSL#3 combination. The results showed that there is a reduction in the inflammation process by enhancement in FOXP3 mRNA expression. VSL#3 in combinations of various probiotics include living strains of: Bifidobacterium (Bifidobacterium prever, Bifidobacterium infantis, and Bifidobacterium longum), and Lactobacillus (Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus delbrueckii, and Lactobacillus plantarum). One more combination of probiotics was studied by Tsuchiya and their team named as Supply Chain Management-III. It consists of living strains of L. acidophilus, Lactococcus helveticus, and Bifidobacterium sp. and the results showed the improvement in abdominal pain and bowel infection. Bifidobacterium and lactobacillus species are mostly used, 70 patients with UC are randomly selected, they divided it into three different treatment groups and provided: Group (1) B. bleve BRO, L. plantarum, Group (2) L. plantarum LP01, L. acidophilus LA02, and Group (3) Placebo. The results showed a decrease in severity of disease, after 2 weeks of observation significant reduction in the symptom of UC was reported.

Steidler and Neirynck performed a study using recombinant technology, Lactococcus lactis was engineered for the secretion of IL-10, given to mice with experimental IBD, mechanism showed, the action of probiotic was similar to a steroid. American college of gastroenterology was conducted, study shows that the effect of single and combinational use of probiotics, team suggested, and single probiotic was not sufficient to cure IBS, but in the combination of two or more probiotic it synergized the effect of each other. The combination of Lactobacillus and Bifidobacterium gives a positive result in IBS. On the basis of recent finding, rare studies are available in the treatment of IBS with probiotics; most of the probiotic research is associated with IBD. These studies explore the beneficial effects of probiotic in IBS also. In some studies, probiotics are combined with probiotics to enhance the potency of formulation. The combination of prebiotic and probiotic is known as synbiotics.

PROBIOTIC AS CRUCIAL LEAD

Probiotics

These are living or killed microorganism, which are beneficial for health by preventing from a diseased state. Basically, they are a part of gut microbiota but due to some intestinal problem, the concentration of probiotic from microbiota goes reduced. Hence, to attain a particular level, probiotics are given externally in various dosage forms to treat IBD. Majorly used probiotic class is lactobacillus and Bifidobacterium. Probiotics are used in freeze-dried and dairy products, also available in powder, tablet, and capsule. Probiotics are also combined with herbal supplements to attain the synergism effect against IBD. As per the recent findings, probiotics act as antibacterial, immunomodulator as well as an intestinal barrier by regulation of microbiota flora.

Curable effect of probiotics in UC

In 2003, the first trial of VSL#3 was done on 25 patients with UC taken randomly to provide VSL#3 combination. The results showed that there is a reduction in the inflammation process by enhancement in FOXP3 mRNA expression. VSL#3 in combinations of various probiotics include living strains of: Bifidobacterium (Bifidobacterium prever, Bifidobacterium infantis, and Bifidobacterium longum), and Lactobacillus (Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus delbrueckii, and Lactobacillus plantarum). One more combination of probiotics was studied by Tsuchiya and their team named as Supply Chain Management-III. It consists of living strains of L. acidophilus, Lactococcus helveticus, and Bifidobacterium sp. and the results showed the improvement in abdominal pain and bowel infection. Bifidobacterium and lactobacillus species are mostly used, 70 patients with UC are randomly selected, they divided it into three different treatment groups and provided: Group (1) B. bleve BRO, L. plantarum, Group (2) L. plantarum LP01, L. acidophilus LA02, and Group (3) Placebo. The results showed a decrease in severity of disease, after 2 weeks of observation significant reduction in the symptom of UC was reported.

Steidler and Neirynck performed a study using recombinant technology, Lactococcus lactis was engineered for the secretion of IL-10, given to mice with experimental IBD, mechanism showed, the action of probiotic was similar to a steroid. American college of gastroenterology was conducted, study shows that the effect of single and combinational use of probiotics, team suggested, and single probiotic was not sufficient to cure IBS, but in the combination of two or more probiotic it synergized the effect of each other. The combination of Lactobacillus and Bifidobacterium gives a positive result in IBS. On the basis of recent finding, rare studies are available in the treatment of IBS with probiotics; most of the probiotic research is associated with IBD. These studies explore the beneficial effects of probiotic in IBS also. In some studies, probiotics are combined with probiotics to enhance the potency of formulation. The combination of prebiotic and probiotic is known as synbiotics.

| Definition                     | Description                                      |
|-------------------------------|--------------------------------------------------|
| Prebiotics                    | These are non-digestible food ingredients         |
| Probiotics                    | These are living/killed microorganism             |
| Synbiotics                    | These are combination of prebiotic and probiotic |

Probiotics boost up the stability of tight junction where probiotics have a different positive effect on epithelial barrier; with the help of tall receptors signal by increasing the production of IgA-cells the permeability of intestinal pathogen is decreased. Probiotics are also helpful in intestinal dysmotility.

Basic property of probiotics during selection for treatment of UC

It should not be toxic. It should have the efficiency to survive in intestine, must have minimum colony-forming unit count, which makes it potent. It should remain effective during the time of storage. All probiotics are not equally active; on the basis of their studies, they can be used in combination form to obtain more results.

Mechanism of probiotics in UC

Prevention of pathogen binding: probiotics inhibit the adherence of pathogen to intestine cell line; hypothetically, it produces a lining on the intestinal mucosa. Probiotics crimp the growth of pathogen bacteria and maintain intraluminal fermentation with the secretion of defensins and signal transducer (NF-KB). The role of probiotics in UC is explained in Figure 2.

Enhancement in barrier function

Probiotics are studied to enhance their effective barrier function; probiotics VSL#3 can protect the intestinal mucosa by enhancing barrier function. Tight junction protein was screwed by activation of F-38 and regulated protein kinase signaling. Probiotics exhibit an anti-inflammatory effect; previous findings show the deduction in the pro-inflammatory

the doctor. These efforts will cure the basic symptoms of UC, i.e., diarrhea and abdominal pain. The following points should be in consideration by people with UC.

- Try to eat in small portions.
- Stay hydrated by drinking water throughout the day.
- Avoid spicy food, always prefer soft food.
- Avoid the food which is rich in fiber (such as nuts, seeds, bran, and beans).
- In case of lactose tolerance limit milk products.
- Avoid consumption of alcohol and caffeine.

- Avoid consumption of alcohol and caffeine.

- In case of lactose tolerance limit milk products.

- Avoid consumption of alcohol and caffeine.
cytokines. Strains of lactobacillus cause inhibition of TNF-α with incite product of IL-8.[38]

List of marketed probiotics

There are many probiotics available in the market. Few of which are mentioned below: Florajen (L. acidophilus), Florajen 3 (B. infantis/L. acidophilus), Acidophilus (L. acidophilus), VSL#3 (B. infantis/L. acidophilus/ Streptococcus thermophilus), Florastor (Saccharomyces boulardii lyo), RisaQuad (L. acidophilus), etc.

CONCLUSION

The use of probiotics in UC leads to increase in the health of the intestine and used to block or manage intestinal disorders by preventing the induction of inflammatory reactions. As a matter of fact, Indian probiotic market is valued at $12 million in 2011, is expected to witness a compound annual growth rate of 11% by 2016. Probiotics are cheaper than conventional drug therapies, improbable to enhance the incidence of antibiotic resistance and they help to manage intestine. A combination of probiotic with herbal drugs could be a realistic approach with negligible side effects. Furthermore, these strategies can provide therapeutic beneficence to colitis suffered patients.

ACKNOWLEDGMENT

The authors are like to acknowledge ISF College of Pharmacy, Moga, Punjab, India, and its dedicated research team for supporting and motivating us to write this mini-review.

REFERENCES

1. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: A systematic review. Clin Gastroenterol Hepatol 2018;16:343-56000.
2. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 2017;26:349-55.
3. Isene R, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: Results from a prospective, population-based European inception cohort. Scand J Gastroenterol 2015;50:300-5.
4. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001;96:3341-7.
5. Manichanh C, Borruel N, Casellas F, Guarner F. The
gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012;9:599-608.
6. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904.
7. Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol 2014;20:14126-31.
8. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;130:396S-402.
9. Ko JZ, Abraham JP, Shih DQ. Pathogenesis of Crohn’s disease and ulcerative colitis-related strictures. In: Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications. United States: Academic Press; 2018. p. 35-41.
10. Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E. Podoplanin in inflammation and cancer. Int J Mol Sci 2019;20:E707.
11. Arora N, Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J 2016;24:458-72.
12. Duijvestein M, Battatt R, Vande Casteele N, D’Haens GR, Sandborn WJ, Khanna R, et al. Novel therapies and treatment strategies for patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2018;16:129-46.
13. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 2009;122:599-604.
14. Feuerstein JD, Cheifetz AS. Ulcerative colitis: Epidemiology, diagnosis, and management. Mayo Clin Proc 2014;89:1553-63.
15. Head KA, Jurenka JS. Inflammatory bowel disease Part 1: Ulcerative colitis–pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003;8:247-83.
16. Abdu-Allah HH, El-Shorbagi AN, Abdel-Moty SG, El-Awady R, Abdel-Alim AA. 5-Aminosalicylic acid (5-ASA): A unique anti-inflammatory salicylate. Med Chem (Los Angeles) 2016;6:306-15.
17. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: Current perspectives. Pharmacol Res 2002;46:1-6.
18. Jensen LB, Magnusson E, Gunnarsson L, Vermeeren C, Nielsen HM, Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm 2010;390:53-60.
19. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4:1118-23.
20. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 2011;63:629-42.
21. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferr F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36.
22. Lautenschlager C, Schmidt C, Fischer D, Stallmach A. State of the art: Therapeutical strategies for the treatment of inflammatory bowel disease. Curr Drug Ther 2013;8:99-120.
23. Paschos P, Katsoula A, Giouleme O, Tsapas A. P670 comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. J Crohn’s Colitis 2018;12 Suppl 1:S449-50.
24. Sokolowska A, Bednarz R, Paczewicz M, Georgiades JA, Wilusz T, Polanowski A. Colostrum from different mammalian species-a rich source of colostrinin. Int Dairy J 2008;18:204-9.
25. Robinson A, Thompson DG, Wilkin D, Roberts C, Northwest Gastrointestinal Research Group. Guided self-management and patient-directed follow-up of ulcerative colitis: A randomised trial. Lancet 2001;358:976-81.
26. Derixx LA, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol 2016;30:55-71.
27. Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, et al. Efficacy of probiotic treatment with *Bifidobacterium longum* 536 for induction of remission in active ulcerative colitis: A randomised, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28:67-74.
28. Lu S, Wang L, Zhang W, Zhang Z, Liu L, Wang Y, et al. Ulcerative colitis with acute pleurisy: A case report and review of the literature. Medicine (Baltimore) 2017;96:e7630.
29. Palumbo VD, Romeo M, Marino Gammazzac A, Carini F, Damiani P, Damiano G, et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:372-7.
30. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
31. Delroisse JM, Bouvain AL, Parmentier I, Dauphin RD, Vandenbol M, Portetelle D. Quantification of *Bifidobacterium* spp. and *Lactobacillus* spp. in rat fecal samples by real-time PCR. Microbiol Res 2008;163:663-70.
32. Garcia Trallero O, Herrera Serrano L, Bibián Inglés M, Roche Vallés D, Rodriguez AM. Effect of the administration of a probiotic with a combination of *Lactobacillus* and *Bifidobacterium* strains on antibiotic-associated diarrhea. Rev Esp Quimioter 2019;32:268-72.
33. Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O’Connell PR. *Desulfovibrio* bacterial species are increased in ulcerative colitis. Dis Colon Rectum 2010;53:1530-6.
34. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal
35. Biagioli M, Capobianco D, Carino A, Marchianò S, Fiorucci C, Ricci P, et al. Divergent effectiveness of multispecies probiotic preparations on intestinal microbiota structure depends on metabolic properties. Nutrients 2019;11:E325.
36. Peng M, Patel P, Nagarajan V, Bernhardt C, Carrion M, Biswas D. Feasible options to control colonization of enteric pathogens with designed synbiotics. In: Dietary Interventions in Gastrointestinal Diseases. United States: Academic Press; 2019. p. 135-49.
37. Ohland CL, Macnaughton WK. Probiotic Bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010;298:G807-19.
38. Plaza-Díaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Immune-mediated mechanisms of action of probiotics and synbiotics in treating pediatric intestinal diseases. Nutrients 2018;10:E42.

Source of Support: Nil. Conflicts of Interest: None declared.